Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutrient label comments

This article was originally published in The Tan Sheet

Executive Summary

FDA extends to April 30 the deadline for comments on its proposed rulemaking concerning percent daily value information allowed on nutrition facts and supplement facts labels. The agency published an advanced notice of proposed rulemaking on Nov. 2 with a 90-day comment period. Dietary supplement industry stakeholders claim the proposal to use estimated average requirements to set daily values for the labels could reduce existing values and lead to lower nutrient levels in food (1"The Tan Sheet" Nov. 12, 2007, p. 3)...

You may also be interested in...



Industry Speaks Up Against Using EARs To Set Daily Nutrient Values

Dietary supplement industry stakeholders contend an FDA proposal to use estimated average requirements to set daily values for nutrition and supplement facts labels could reduce existing values and lead to lower nutrient levels in food

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel